Journey Medical Turns Profitable in Q2 2026

Journey Medical Corporation has signaled a robust financial turnaround by reporting positive EBITDA in the second quarter of 2026. The company achieved a 23% year-over-year increase in total net product revenue while successfully maintaining flat operating expenses, marking a critical inflection point for profitability. Management has defined 2026 as a "breakout year," projecting sustainable financial performance and cash flow positivity for the remainder of the fiscal year.

Profitability Shift and Revenue Momentum

The most striking aspect of the financial statements is the direct translation of revenue growth into bottom-line results:

■Total net product revenue surged by 23% year-over-year.

■Positive EBITDA was achieved while keeping operating expenses flat.

■Improved profitability was bolstered by a rising Average Selling Price (ASP) driven by a transition to reimbursed channels.

Amrozi's Market Dominance and Prescription Growth

Journey Medical’s flagship product, Amrozi, drove revenue growth by demonstrating superior efficacy against its competitor Oracea:

■Amrozi revenue reached $8.1 million.

■Total prescriptions increased by 20% sequentially.

■The unique prescriber base expanded significantly to over 4.5 thousand.

■High patient satisfaction and rapid clinical onset of action continue to fuel demand.

2026 Breakout Strategy and Commercial Expansion

Management anticipates sustained cash flow positivity, underpinned by several strategic growth drivers:

■Urox Cream, a non-steroidal anti-itch product, was deployed to the sales force in July 2026.

■Market access improved significantly, with high-quality formulary coverage reaching 38% of commercial lives.

■Successful integration with all top three GPOs secured planned access to 169 million out of 192 million covered commercial lives in the U.S.

■The company is actively pursuing out-licensing in non-U.S. territories and exploring in-licensing of new dermatology assets.

Management's linkage of ASP growth to reimbursed channels is strategically sound. From an EM strategy perspective, optimizing market access to increase yield per prescription is the most efficient path to margin expansion in the healthcare sector. Journey Medical securing access to 169 million commercial lives increases the upside risk for revenue revisions in the coming quarters.